Clinical Trial

Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of BPN14770 in participants with severe renal impairment and those with normal renal function.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-06-02; most recent amendment 2026-02-24.
Status change: Recruiting → Completed 2026-02-24
Status change: Not Yet Recruiting → Recruiting 2025-08-15
Trial Details
NCT Number NCT07012005
Lead Sponsor Shionogi
Conditions Renal Impairment
Enrollment 14 participants
Start Date 2025-08-25
Primary Completion 2025-12-15 (estimated)
Study Completion 2025-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-02-27